Effects of budesonide and fluticasone on 24-hour plasma cortisol: A dose-response study

American Journal of Respiratory and Critical Care Medicine

Volumn 156, Issue 6, 1997, Pages 1746-1751

  Donnelly, Richard ^a   Williams, Kenneth M ^b   Baker, A Barry ^b   Badcock, Caro Anne ^b   Day, Richard O ^b   Seale, J Paul ^b  

^a University of Sydney   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STEROID THERAPY;

EID: 0031467943     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.156.6.9703003     Document Type: Article

References (25)

1. Kamada, A. K., S. J. Szefler, R. J. Martin, H. A. Boushey, V. M. Chinchilli, J. M. Drazen, J. E. Fish, E. Israel, S. C. Lazarus, and R. F. Lemanske. 1996. Issues in the use of inhaled glucocorticoids. Am. J. Respir. Crit. Care Med. 153:1739-1748.
2. Barnes, N. C., G. Marone, G. U. DiMaria, S. Visser, I. Utama, and S. L. Payne. 1993. A comparison of fluticasone propionate 1 mg daily with beclomethasone dipropionate 2 mg daily in the treatment of severe asthma. Eur. Respir. J. 6:877-885.
3. Ayres, J. G., E. D. Bateman, B. Lundback and T. A. J. Harris. 1995. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur. Respir. J. 8:579-586.
4. Langdon, C. G., and J. Thompson. 1994. A multicentre study to compare the efficacy and safety of inhaled fluticasone propionate and budesonide via metered-dose inhalers in adults with mild-to-moderate asthma. Br. J. Clin. Res. 5:73-84.
5. Dahl, R., B. Lundback, J. L. Malo, et al. 1993. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 104:1352-1358.
6. Fabbri, L., P. S. Burge, L. Croonenborgh, et al. 1993. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 48:817-823.
7. Grove, A., C. Allam, L. C. McFarlane, G. McPhate, C. M. Jackson, and B. J. Lipworth. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone in normal subjects. Br. J. Clin. Pharmacol. 38:521-525.
8. Clark, D. J., A. Grove, R. I. Cargill, and B. J. Lipworth. 1996. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 51:262-266.
9. Grahnen, A., S. A. Eckernas, R. M. Brundin, and A. Ling-Andersson. 1994. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br. J. Clin. Pharmacol. 38:521-525.
10. Todd, G., K. Dunlop, J. McNaboe, M. F. Ryan, D. Carson, and M. D. Shields. 1996. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 348:27-29.
11. Jennings, B. H., K. E. Andersson, and S. A. Johansson. 1990. Assessment of the systemic effects of inhaled glucocortocoids: the influence of blood sampling techniques and frequency on plasma cortisol and leucocytes. Eur. J. Clin. Pharmacol. 39:127-131.
12. Ruberg, S. L. 1995. Dose-response studies: II. Analysis and interpretation. J. Biopharm. Stat. 5:15-42.
13. Davidian, M., and D. M. Giltinan. 1993. Some general estimation methods for nonlinear mixed-effects models. J. Biopharm. Stat. 3:23-55.
14. Boorsma, M., N. Andersson, P. Larsson, and A. Ullman 1996. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur. Respir. J. 9:1427-1432.
15. Nikolaizik, W. H., J. L. Marchant, M. A. Preece, and J. O. Warner. 1996. Nocturnal cortisol secretion in healthy adults before and after inhalation of budesonide. Am. J. Respir. Crit. Care Med. 153:97-101.
16. A Six-Part Asthma Management Program. 1995. Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop. U.S. Government Printing Office, Washington, DC. NIH Publication No. 95-365992.
17. Clark, D. J., and B. J. Lipworth. 1997. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 52:55-58.
18. English, A. F., M. S. Neate, D. J. Quint, and M. Sareen. 1994. Biological activities of some corticosteroids used in asthma (abstract). Am. J. Respir. Crit. Care Med. 149:A212.
19. Brattsand, R., A. Thalen, K. Roempke, L. Kallstrom, and E. Gruvstad. 1982. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. Eur. J. Respir. Dis. 63(Suppl. 122):62-73.
20. Brattsand, R., and A. I. Axelsson. 1992. New inhaled glucocorticosteroids. In P. J. Barnes, editor. New Drugs for Asthma, Vol. 2. IBC Technical Services, London. 193-208.
21. Lipworth, B. J. 1995. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 50:105-110.
22. Thorssen, L., S. Edsbacker, and T.-B. Conradson. 1994. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur. Respir. J. 7:1839-1844.
23. Melchor, R., M. F. Biddiscome, V. H. F. Mak, M. D. Short, and S. G. Spiro. 1993. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 48:506-511.
24. Clark, D. J., L. C. McFarlane, and B. J. Lipworth. 1997. Adrenal activity with chronic dosing of fluticasone propionate compared with budesonide in asthmatic children. Thorax (In press)
25. Grove, A., L. C. McFarlane, C. M. Jackson, et al. 1996. Effects of short-term exposure to high-dose inhaled corticosteroids on novel markers of bone metabolism. Eur. J. Clin. Pharmacol. 503:275-277.